TGFB3
Transforming growth factor beta-3 proprotein [Cleaved into: Latency-associated peptide
As of the edition of 20 October 2026, TGFB3 (transforming growth factor beta-3 proprotein [Cleaved into: Latency-associated peptide, UniProt P10600) has 4 drugs tested at it and 6 companies on the list, 2 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P10600
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- Secreted
- Solved structures
- 11
- Disease areas
- Cancer; Blood and lymph; Inherited and neonatal; Urinary and reproductive; Lungs and airways; Digestive system; Pregnancy and women's health; Skin and connective tissue
- Registered trials of its drugs
- 135
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Stopped | 2 |
| Status not established | 1 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Luspatercept | Marketed | Phase 4 | Ends 2031 |
| Bintrafusp alfa | Stopped | Phase 3 | none listed |
| Fresolimumab | Stopped | Phase 2 | none listed |
| RO7303509 | Status not established | Phase 1 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 1 |
| Engaged | 2 |
| Undetermined | 1 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| Bristol Myers Squibb | Route B |
| Merck KGaA | Route A |
| GSK | Route A |
The other 3 companies at TGFB3
In the product6 companies in all; 3 are not named here, and no score is.
See the 6 companies at TGFB3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.